Platelet interaction with type III collagen is mediated by several platelet receptors that recognize specific sequences in collagen. We previously described an octapeptide KP*GEP*GPK within the ␣(1)III-CB4 fragment that binds to platelets and specifically inhibits platelet aggregation induced by type III collagen. In this study, we demonstrated that the octapeptide prevented platelet contact and spreading on type III collagen and subendothelium under static and flow conditions. Platelets adhered to the immobilized octapeptide, and antibodies directed against other platelet collagen receptors (glycoprotein (GP) Ia/IIa, GP IV, p65, p47) did not impair this adhesion. The platelet octapeptide receptor was identified by ligand blotting as a protein doublet with molecular masses of 68 and 72 kDa and does not correspond to any other already known platelet collagen receptors (GP Ia, GP IV GP VI, and p65). Our results indicate that a specific type III collagen receptor, expressed on the platelet surface, is involved in the first stages of platelet type III collagen interaction.
Type I and type III collagens are predominant vascular thrombogenic molecules. Platelet interaction with collagen is a complex phenomenon, involving several platelet membrane glycoproteins (1) and nonintegrin receptors (2) , with different binding sites on the collagen molecule coming into play in a specific order during the sequential phases of platelet collagen interaction, i.e. platelet contact, spreading, and aggregation. GP 1 Ia/IIa (integrin ␣ 2 /␤ 1 , very late antigen-2) is a major collagen receptor. It binds to type I collagen via specific sequences within the ␣1(I)-CB3 fragment: residues 435-438 (DGEA) 2 (3) and residues 502-516 with an essential GER sequence (4) , and within the ␣2(I)-CB4 peptide (5) . Platelet GP Ia/IIa binds to the ␣1(III)-CB4 peptide on type III collagen and, more precisely, to a GGPP*GPR sequence (residues 522-528) (6) . However, the role of GP Ia/IIa in platelet activation remains poorly understood, as it is not involved in the initial platelet contact (7) and it indirectly affects spleen tyrosine kinase phosphorylation during signal transduction (8) . Spleen tyrosine kinase phosphorylation is induced by the binding of platelet GP VI to the GPP* sequences contained in the triple helical structure of collagen (9) . Moreover, collagen-related peptides composed of a GPP* sequence repeats, are able to induce platelet aggregation via platelet GP VI (10) . The platelet membrane glycoprotein GP IV (11) has been proposed as a collagen receptor, but its role seems to be restricted to type V collagen (12) . Finally, Chiang et al. identified p65 as a specific type I collagen receptor that binds the ␣1(I)-CB5 fragment (13) (14) (15) and p47, which recognizes type III collagen (16) .
Previous studies from our laboratory showed that platelets bind to specific sequences of type I (17) and type III collagens (18 -20) . In Particular, platelets react with an octapeptide in type III collagen that is located within the ␣1(III)-CB4 fragment (residues 497-504). This octapeptide (KP*GEP*GPK) specifically inhibits platelet aggregation induced by type III collagen (21, 22) by blocking the phosphorylation of pleckstrin (23) and the activation of GP IIb/IIIa (24) .
In the present paper, we characterize the role of this octapeptide in platelet contact and spreading on type III collagen and subendothelium under static and flow conditions. The octapeptide recognized a doublet of platelet proteins with molecular mass of 68 -72 kDa. The major protein (68 kDa) named TII-ICBP (type III collagen-binding protein) is a specific platelet receptor for type III collagen that is involved in the first step of platelet collagen interaction.
EXPERIMENTAL PROCEDURES
Reagents-The octapeptide KP*GEP*GPK was synthesized by Genosphère Biotechnologies (Paris, France). Type I and type III collagens (Chemicon, Temecula, CA) were dialyzed overnight against 100 mM phosphate buffer, pH 7.4, and polymerized by heating for 5 min at 33°C before use. Collagen-chain composition and purity were assessed by SDS-PAGE (25) . Orthophenylenediamine dihydrochloride and HRPconjugated streptavidin were from Life Technologies, Inc. (Cergy-Pontoise, France). Biotinylated-convulxin was a generous gift from Dr. M. Jandrot-Perrus (Département d'Hématologie, Hémostase et Thrombose, Hôpital Bichat, Paris, France). Tween 20, Hepes, polylysine, Nethylmaleimide, and other chemical compounds were from Sigma-Aldrich (Saint-Quentin-Fallavier, France).
Antibodies-The anti-GP Ia (6F1), anti-p65 and anti-p47, and anti-GP IV (FA6) antibodies were kindly, donated respectively, by Dr. B. S. Coller (Mount Sinai Medical Center, New York, NY), Dr. T. M. Chiang (Veterans Administration Medical Center, Memphis, TN), and Dr. L. Edelman (Institut Pasteur, Paris, France). HRP-conjugated antibodies directed against mouse or rabbit immunoglobulins were purchased from Dako (Glostrup, Denmark).
Preparation of Platelets-Blood obtained from consenting healthy human donors was anticoagulated with either acid-citrate-dextrose for static assays or 10 units/ml Fraxiparin (Sanofi Winthrop, Toulouse, France) for platelet adhesion under flow conditions.
For static assays, platelet-rich plasma and washed platelets were prepared as described previously (26) . After the last wash, platelets were resuspended in the appropriate buffers used for adhesion or aggregation Platelet-Collagen Interactions-Platelet contact with collagen in suspension was evaluated as described elsewhere (26) . Platelet adhesion to immobilized collagen or octapeptide was studied according to Tandon et al. (11) . Adherent platelets were quantified colorimetrically as described by Bellavite et al. (27) . Results are the means of three different experiments run in triplicate (Ϯ S.E.). Platelet aggregation was allowed to proceed in an aggregometer (Chrono-Log Corp., Harvertown, PA). Platelet-rich plasma was incubated with [
14 C]5HT (Amersham Life Science, Little Chalfont, United Kingdom) and radiolabeled serotonin release was measured as described previously (26) .
Platelet Studies under Flow-Flow assays were done in parallel flow chambers, as described by Sakariassen et al. (28) . Collagen (50 g/cm 2 ) or octapeptide (50 g/cm 2 ) was sprayed onto Thermanox coverslips (Nalgen Nunc International, Naperville, IL). HUVEC matrix was obtained after ammonia-induced lysis of confluent cells as described previously (7). For the negative control, coverslips were sprayed with BSA (50 g/cm 2 ). Two different shear rates (300 and 1500 s
Ϫ1
) were applied for 5 min at 37°C. After perfusion, coverslips were washed three times in Hepes buffer. Platelets were fixed with 0.5% glutaraldehyde and stained with DiffQuick ® (Dade AG, Dü digen, Switzerland). The percentage of the surface covered by platelet was estimated by examining 10 microscope fields with a camera coupled to picture analysis software (Biocom Co., Les Ulis, France).
Inhibition Studies-Before measuring platelet adhesion to the octapeptide, platelet suspensions were preincubated for 10 min at 37°C with monoclonal antibodies directed against GP Ia/IIa (6F1; 10 g/ml), GP IV (FA6; 10 g/ml), anti-p65 (60 g/ml), or anti-p47 (60 g/ml) (final concentrations).
To inhibit platelet adhesion and aggregation in flow experiments, the octapeptide (0.5 or 0.25 mM, final concentration) was added to whole blood and incubated for 5 min at 37°C before the perfusion.
Octapeptide Biotinylation-The octapeptide was resuspended in PBS at 2 mg/ml. EZ-Link Sulfo-NHS-LC-Biotin (Pierce) (75 g/ml, final concentration) was added to the solution and incubated for 2 h at room temperature. The biotinylated octapeptide was separated from free Sulfo-NHS-Biotin by filtration on a Superose 12 HR column (Amersham Pharmacia Biotech, Uppsala, Sweden).
Octapeptide Binding to Platelets-Washed platelets (4 ϫ 10 7 ) were adsorbed by centrifugation (1,200 ϫ g) onto polylysine (50 g/ml)-coated wells of microtiter plates. Adsorbed platelets were incubated with biotinylated octapeptide (10 -400 g/ml) in Tyrode's buffer for 1 h at room temperature and washed three times with the same buffer. Platelets were further incubated for 1 h with HRP-conjugated streptavidin (1 g/ml) and washed. The HRP was revealed with orthophenylenediamine dihydrochloride, and the optical density was read at 490 nm.
Competition Experiments-Washed platelets were incubated with the biotinylated octapeptide (50 g/ml) and with the unlabeled octapeptide (0.75, 1.5, or 3 mg/ml) for 1 h at room temperature in Tyrode's buffer and washed three times in the same buffer. The biotinylated octapeptide bound to the platelet surface was revealed by HRP-streptavidin (1 g/ml) as above.
Ligand Blotting-Platelet proteins were separated by SDS-PAGE and transferred onto a nitrocellulose membrane. The membrane was saturated with 5% skim milk in TBS, washed in TBS containing 0.05% Tween 20 (TBS-Tween), and incubated with biotinylated octapeptide (15 g/ml), 6F1 (10 g/ml), anti-p65 antibody (20 g/ml), or biotinylated convulxin (1 g/ml). For convulxin, the incubations were performed in PBS or PBS-Tween. The reaction was revealed by HRP-streptavidin (1 g/ml) or HRP antibodies directed against mouse or rabbit IgG (respectively, at 0.5 or 0.15 g/ml) HRP was visualized by chemiluminescence on Kodak X-Omat film.
Two-dimensional Electrophoresis-Two dimensional electrophoresis was performed using the Bio-Rad system for mini gels. For the first dimension, 50 g of platelet proteins were loaded onto the agarose gel containing an ampholyte gradient in the pH range of 3-10 (Bio-lyte ® , Bio-Rad). For the second dimension, a 7.5% acrylamide gel was used. After the second run, proteins were transferred onto a nitrocellulose membrane and TIIICBP was detected with the biotinylated octapeptide as described above.
RESULTS
Platelet Contact with Collagen-Platelet contact was induced by 20 g/ml (final concentration) of collagen fibers in suspension. Similar numbers of platelets remained associated with type I or type III collagen fibers (Fig. 1, A and B, 2 ). Platelet interaction with type III collagen was partially inhibited by 0.25 mM octapeptide (Fig. 1B, 3) , and a quasi-complete inhibition was observed in presence of 0.5 mM octapeptide (Fig. 1B, 4) . In contrast, the contact between platelet and type I collagen (Fig.  1B) was not affected by the octapeptide even at 0.5 mM.
Platelet Adhesion to Immobilized type III Collagen, Octapeptide, and HUVEC Matrix-Under static conditions, similar numbers of platelets adhered to immobilized type III collagen or octapeptide (Fig. 2 ) and comparable amounts of serotonin (ϳ50%) were released by adherent platelets.
Platelet adhesion to immobilized type III collagen (Fig. 3A ) was partially inhibited (44 Ϯ 1%) by 0.25 mM octapeptide (Fig.  3A, 3) ,and inhibition was quasi-complete in the presence of 0.5 mM octapeptide (Fig. 3A, 4) . Under these static conditions, fewer platelets adhered to the HUVEC matrix and 66 Ϯ 1.5% and 88 Ϯ 2% inhibition were observed in the presence of, respectively, 25 mM (Fig. 3B, 3 ) and 0.5 mM octapeptide (Fig.  3B, 4) .
Platelet Adhesion and Aggregation under Flow-Studies under flow were performed at two shear rates: 300 and 1500 s Ϫ1 (Fig. 4, A and B) . Under shear conditions, type I and type III collagens were equal potent inducers of platelet adhesion and aggregation (20 -25% of the exposed slide surfaces were covered with platelets at high and low shear rates). However, both very dense aggregates and individual scattered adherent platelets were observed on type III collagen (Fig. 4, A and B, 1) while on type I collagen most of the platelets adhered individually and only some them formed small aggregates (Fig. 4, A and B,  7) . Under flow conditions, fewer platelets adhered to the octapeptide (7% at 300 s Ϫ1 and 13% at 1500 s Ϫ1 ), fewer aggregates were formed, and they appeared to be less densely packed at the higher shear rate (Fig. 4B, 4) than the lower one (Fig. 4A,  4) . At both shear rates, 0.25 mM octapeptide partially inhibited platelet adhesion (around 50%) and aggregate formation on type III collagen (Fig. 4, A and B, 2 ) and on octapeptide (Fig. 4,  A and B, 5) . On type III collagen, 0.5 mM octapeptide almost (Fig. 4A, 3) , whereas at 1500 s Ϫ1 residual adhesion (5% of the surface covered) and a few aggregates were still observed (Fig. 4B, 3) . In the presence of 0.5 mM octapeptide, platelet adhesion to octapeptide was almost completely inhibited, at both shear rates (Fig. 4, A and B, 6 ). In contrast, platelet adherence to type I collagen was not inhibited by the octapeptide even at 0.5 mM (Fig. 4, A and B, 8 and 9) .
Octapeptide Binding to Platelets-Binding experiments were performed with the biotinylated-octapeptide. The saturation of the octapeptide binding sites on 4.10 7 platelets was obtained with a concentration of 200 nM octapeptide. The half-saturation was estimated at a concentration of 35 nM octapeptide (Fig. 5A) . The specificity of the reaction was established with the unlabeled octapeptide; one molecule of the biotinylated octapeptide was displaced by about 60-fold excess of the unconjugated octapeptide (Fig. 5B) .
Evidence for New TIIICBP-After separation of platelet proteins by SDS-PAGE and ligand blotting, the biotinylated octapeptide bound to two platelet proteins with molecular masses of 68 and 72 kDa (Fig. 6A ). This binding was inhibited by a 100-fold excess of unlabeled peptide (data not shown). After reduction, these proteins presented apparent molecular masses of 73 and 77 kDa, indicating the presence of intrachain disulfide bounds. Using a two-dimensional electrophoresis system, we determined the pH i of both bands. The 68-kDa protein comprised four isoforms with pH i situated between 5.6 and 5.9. The 72-kDa protein had a single form with a pH i of 6.9 (Fig.   6B ). Other already known platelet collagen receptors, namely GP VI, p65, and GP Ia, were revealed by ligand and immunoblotting. Antibodies directed against GP Ia or p65 and convulxin, which binds to GP VI, did not recognize the protein doublet (Fig. 7A) . Moreover platelet adhesion to the immobilized octapeptide (Fig. 7B) was not inhibited by different antibodies: anti-p65 (Fig. 7B, 3) , anti-p47 (Fig. 7B, 4) , anti-GP IV (Fig. 7B, 5) , and anti-GP Ia (Fig. 7B, 6 ).
DISCUSSION
The type III collagen sequence KP*GEP*GPK, present within the ␣1(III)-CB4 peptide in positions 497-504, was first described as an inducer of platelet adhesion under static conditions (19) and then as a specific inhibitor of platelet aggregation induced by type III collagen (22) . Using a protein sequence data base (Swiss-Prot), we verified that this sequence is specific to type III collagen. It is present in chicken, bovine, mouse, and human type III collagens but not in any other collagen type or any other protein. This octapeptide appears to be the minimal collagen sequence reacting with platelets, since the pentapeptide GEP*GP was inactive (29) . The activity of this peptide seems to be linked to its rigidity confer by its high content of imino acids (P and P*). Moreover, it contains two symmetrical tripeptides KP*G and GPK, which are linked by a spacer (EP*). The presence of P* in the spacer prevents a free rotation of the sequence and the conformation of the two tripeptides supports platelet accessibility. Moreover, the octapeptide does not contain the GPP* sequence involved in platelet aggregation mediated by GP VI (31) . In the present study, we investigated the role of the octapeptide in the first steps of platelet activation, i.e. platelet collagen contact and spreading under static conditions, and platelet collagen interactions under flow conditions.
In our assay, platelet contact with collagen is cation-independent (26), does not induce platelet activation, and is not mediated by GP Ia/IIa, GP IIb/IIIa, or GP IV (7). On the other hand, platelet contact with type III collagen was specifically inhibited by the octapeptide, indicating that this peptide binds to a primary platelet receptor for this particular collagen. The absence of octapeptide initial binding peptide to GP Ia/IIa confirms that the latter is not involved in the initial contact between platelets and collagen (7). The octapeptide also inhibits platelet spreading on immobilized type III collagen. Moreover, octapeptide immobilized on plastic induced platelet adhesion and serotonin release equivalent to those of type III /l) in adhesion buffer were adsorbed onto immobilized type III collagen or octapeptide and incubated for 1 h at 37°C. The number of adherent platelets was determined colorimetrically (27) , and serotonin release was measured by counting the radioactivity in the supernatants after centrifugation of the multititer plates. Results are the means of three determinations run in triplicate (Ϯ S.E.).
FIG. 3. Effect of octapeptide on platelet adhesion to immobilized type III collagen or HUVEC matrix.
Platelets were incubated for 5 min at 37°C with 0.25 or 0.5 mM octapeptide before to being adsorbed onto the microwells coated with type III collagen (A) or HU-VEC matrix (B) and further incubated for 1 h at 37°C. Platelet counts were determined colorimetrically. Platelets were incubated on: 1, control (BSA); 2, type III collagen or HUVEC matrix; 3, in the presence of 0.25 mM octapeptide; 4, in the presence of 0.5 mM octapeptide. Results are the means of three determinations run in triplicate (Ϯ S.E.).
collagen. The proximity of octapeptides in the wells favored platelet adhesion and help to cluster high numbers of platelet receptors on one side of the platelets. The clustering of these receptors could induce platelet activation, as assessed by serotonin release and the phosphorylation of signal proteins under these conditions (data not shown). Moreover, platelet adhesion to the octapeptide was not inhibited by antibodies directed against other collagen receptors including GP Ia, GP IV, p65, and p47 (Fig. 7B) . This observation further supports that GP Ia/IIa is not involved in the first steps of platelet type III collagen interaction (7) . Platelet adhesion to HUVEC matrix under static conditions was inhibited by 0.5 mM octapeptide, but the inhibition was not complete, indicating that platelets may also react with other molecules expressed in the matrix.
Under flow conditions, the octapeptide inhibited platelet adhesion and aggregation induced by type III collagen at two shear rates (300 and 1500 s Ϫ1 ) but had no effect on platelet type I collagen interaction, supporting the high specificity of its action. At low shear rate (300 s Ϫ1 ), on the octapeptide fewer and smaller aggregates were formed, and this observation was further accentuated at the high shear rate (1500 s Ϫ1 ). Thus, at the low shear rate, as under static conditions, platelet adhesion was followed by platelet activation. The surface covered at low shear rate was higher (7%) than that observed (1%) by Verkleij et al. (30) for the CB4(III)-4 peptide, which contains the octapeptide, probably because this sequence is less accessible in a larger peptide. At the high shear rate (1500 s Ϫ1 ), the absence of platelet aggregate formation on the octapeptide could be due to immobilized on polylysine were incubated with increasing concentrations of biotinylatedoctapeptide, ranging from 10 to 400 g/ml for 1 h at room temperature. The bound octapeptide was measured as described under "Experimental Procedures." B, competition. Immobilized platelets (4 ϫ 10 7 ) were incubated with 50 g/ml biotinylated-octapeptide in the presence of 0.75-3 mg/ml unlabeled octapeptide. the inability of plasma von Willebrand factor (vWF) to bind to the octapeptide like to CB4(III)-4 (30), because vWF is necessary for the maintenance of platelet aggregates at a high shear rate. The binding of plasma vWF to the entire type III collagen could explain the presence of sparse small aggregates when platelets where incubated with 0.5 mM octapeptide before perfusion (Fig. 4B, 3) .
The specificity of the binding was assessed with the competition studies: the binding was displaced by a 60-fold excess of unlabeled octapeptide. Ligand blotting, after SDS-PAGE of total platelet proteins, showed that the octapeptide bound to a doublet of proteins with molecular masses of 68 (major) and 72 kDa. This dual binding indicates that the octapeptide also recognizes its platelet receptor under denatured conditions. The protein doublet does not correspond to any already known collagen receptor. The doublet is not stained by the Schiff reagent, indicating that it is not glycosylated. The major band was composed by four isoforms with different phosphorylation states, as observed after immunoblotting with an anti-phosphotyrosine kinase that labeled two spots (data not shown).
In conclusion, platelet adhesion to type III collagen occurs via a specific non integrin receptor, TIIICBP. This receptor is involved in the contact between platelet and collagen, and our studies under flow conditions demonstrated that platelet TIII-CBP reacted directly with the octapeptide or type III collagen. Further investigations are needed to elucidate octapeptideinduced activation pathway and to determine whether eventual interactions with other collagen receptors, for example GP VI, could reinforce platelet aggregation. Nonetheless, results presented herein allow us to complete the model proposed by Verkleij et al. (32) . Unlike the collagen-related peptides used in their study (32) , the octapeptide favored platelet adhesion under flow conditions, as shown in Fig. 8 . During the first step, arrest of platelets on type III collagen, platelet TIIICBP would bind to the octapeptide in CB4(III)-4 (positions 487-495). Very close to this first interaction, platelet GP Ib would react with vWF bound in CB4(III)-7 (residues 541-558) (32), and the adhesion would then be stabilized by the binding of GP Ia/IIa to CB4(III)6/7 (residues 522-528) (30) . Finally, the binding of GP VI to the collagen triple helix, and the eventual participation of other receptors (p47?) (16) would reinforce platelet activation, leading to the formation of large thrombi. Taken together, the results of these studies show that type III collagen has several platelet-binding sites condensed in a small region within the CB4 peptide, a system that could provide a solid foundation for platelet adhesion and aggregation, thereby assuring adequate thrombus formation. FIG. 8 . Schematic presentation of platelet interaction with type III collagen. I, contact and low activation. Platelet TIIICBP (black V) would recognize the octapeptide ␣1(III)CB4 (K*PGEP*GPK) (thick black arrow) on type III collagen. Then GP Ib (black semicircle) would recognize vWF (white oval) bound to ␣1(III)CB4 -6/7 and GPIa/ IIa (white V) would bind to ␣1(III)CB4 (GGPP*GPR) (thick white arrow). The binding of all these receptors would slightly activate platelets for stage II. II, full activation and aggregation. GP VI (white crescent moon) would recognize the GPP* sequence in the collagen triple helix and other collagen receptors such as p47 would bind to collagen leading to the full activation of platelets with the binding of secreted fibrinogen (black flag) to GP IIbIIIa and (white cylinder) thrombus formation. FIG. 6. Identification of octapeptide-binding proteins. A, ligand blots on platelet proteins. Proteins from a platelet lysate under reduced (R) and nonreduced (NR) conditions were separated by SDS-PAGE, transferred onto nitrocellulose, and incubated with the biotinylated octapeptide (15 g/ml). The reaction was revealed by HRP-streptavidin and chemiluminescence. The kDa of the labeled bands was determined by comparison with the standards. B, twodimensional electrophoresis. Platelet proteins were first separated on an ampholyte gradient pH 3-10 and then subjected to 7.5% SDS-PAGE; proteins were transferred onto nitrocellulose, and the membrane was treated as above. The pH i and the kDa were determined by comparison with the standards. 
